References 1. Strine TW, Kobau R, Chapman DP, Thurman DJ, Price P, et al. (2005) Psychological distress, comorbidities, and health behaviors among U. S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 46: 1133–1139. 2. Litt B, Esteller R, Echauz J, D’Alessandro M, Shor R, et al. (2001) Epileptic seizures may begin hours in advance of clinical onset: a report of five patients. Neuron 30: 51–64. 3. Manford M, Hart YM, Sander JW, Shorvon SD (1992) National General Practice Study of Epilepsy: partial seizure patterns in a general population. Neurology 42: 1911–1917. 4. Lieb JP, Babb TL, Engel J, Jr. (1989) Quantitative comparison of cell loss and thiopental-induced EEG changes in human epileptic hippocampus. Epilepsia 30: 147–156. 5. French JA, Williamson PD, Thadani VM, Darcey TM, Mattson RH, et al. (1993) Characteristics of medial temporal lobe epilepsy: Results of history and physical examination. Ann Neurol 34: 774–780. 6. Buckmaster PS (2004) Prolonged infusion of tetrodotoxin does not block mossy fiber sprouting in pilocarpine-treated rats. Epilepsia 45: 452–458. 7. Morimoto K, Fahnestock M, Racine RJ (2004) Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 73: 1–60. 8. Cerso´simo R, Flesler S, Bartuluchi M, Soprano AM, Pomata H, et al. (2011) Mesial temporal lobe epilepsy with hippocampal sclerosis: Study of 42 children. Seizure 20: 131–137. 9. Kanemoto K, Kawasaki J, Miyamoto T, Obayashi H, Nishimura M (2000) Interleukin (IL) 1beta, IL-1alpha, and IL-1 receptor antagonist gene polymor- phisms in patients with temporal lobe epilepsy. Ann Neurol 47: 571–574. 10. Rothwell NJ (1999) Annual review prize lecture cytokines-killers in the brain? J Physiol 514: 3–17. 11. Minami M, Kuraishi Y, Satoh M (1991) Effects of kainic acid on messenger RNA levels of IL-1 beta, IL-6, TNF alpha and LIF in the rat brain. Biochem Biophys. Res Commun 176: 593–598. 12. Jankowsky JL, Patterson PH (2001) The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol 63: 125–149. 13. Ananth C, Gopalakrishnakone P, Kaur C (2003) Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult rats. Hippocampus 13: 375–387. 14. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, et al. (2001) Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 85: 47–51. 15. White CM (1999) Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 39: 111–118. 16. Wood WG, Eckert GP, Igbavboa U, Mu¨ ller WE (2010) Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci 1199: 69–76. 17. Rajanikant GK, Zemke D, Kassab M, Majid A (2007) The therapeutic potential of statins in neurological disorders. Curr Med Chem 14: 103–112. 18. Nath N, Giri S, Prasad R, Singh AK, Singh I (2004) Potential targets of 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 172: 1273–1286. 19. Singh I, Pahan K, Khan M (1998) Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS Lett 426: 342–346. 20. Stanislaus R, Gilg AG, Singh AK, Singh I (2002) Immunomodulation of experimenta autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett 333: 167–170. 21. Paintlia AS, Paintlia MK, Singh AK, Stanislaus R, Gilg AG, et al. (2004) Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res 77: 63–81. 22. Pannu R, Christie DK, Barbosa E, Singh I, Singh AK (2007) Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem 101: 182–200. 23. Balduini W, Mazzoni E, Carloni S, De Simoni MG, Perego C, et al. (2003) Prophylactic but not delayed administration of simvastatin protects against long- lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 34: 2007–2012. 24. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, et al. (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95: 8880–8885. 25. Kirsch C, Eckert GP, Koudinov AR, Muller WE (2003) Brain cholesterol, statins and Alzheimer’s Disease. Pharmacopsychiatry 36: 113–119. 26. Lu D, Goussev A, Chen J, Pannu P, Li Y, et al. (2004) Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 21: 21–32. 27. Devaraj S, Chan E, Jialal I (2006) Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91: 4489–4496. Simvastatin Restrains Exacerbation of Epilepsy 28. Chen SF, Hung TH, Chen CC, Lin KH, Huang YN, et al. (2007) Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sci 81: 288–298. 29. Sierra S, Ramos MC, Molina P, Esteo C, Va´zquez JA, et al. (2011) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain- barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23: 307–318. 30. Ramirez C, Tercero I, Pineda A, Burgos JS (2011) Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimers Dis 24: 161–174. 31. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, et al. (2003) 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23: 11104–11111. 32. Bo Li, Asim Mahmood, Dunyue Lu, Hongtao Wu, Ye Xiong, Changsheng Qu (2009) Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1 level after traumatic brain injury. Neurosurgery 65: 179–186. 33. Asim Mahmood, Anton Goussev, Humaira Kazmi, Changsheng Qu, Dunyue Lu, et al. (2009) Long-term benefits after treatment of traumatic brain injury with simvastatin in rats. Neurosurgery 65: 187–192. 34. Dunyue Lu, Changsheng Qu, Anton Goussev, Hao Jiang, Chang Lu, et al. (2007) Statins Increase Neurogenesis in the Dentate Gyrus, Reduce Delayed Neuronal Death in the Hippocampal CA3 Region, and Improve Spatial Learning in Rat after Traumatic Brain Injury. J Neurotrauma 24: 1132–1146. 35. Jin-Koo Lee, Je-Seong Won, Ph. D., Avtar K, Singh, et al. (2008) Statin Inhibits Kainic Acid-Induced Seizure and Associated Inflammation and Hippocampal Cell Death. Neurosci Lett 440: 260–264. 36. Fabene PF, Bramanti P, Constantin G (2010) The emerging role for chemokines in epilepsy. J Neuroimmunol 224: 22–27. 37. Rizzi M, Perego C, Aliprandi M, Richichi C, Ravizza T, Colella D, et al. (2003) Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis 14: 494–503. 38. Hailer NP, Vogt C, Korf HW, Dehghani F (2005) Interleukin-1b exacerbates and interleukin-1 receptor antagonist attenuates neuronal injury and microglial activation after excitotoxic damage in organotypic hippocampal slice cultures. Eur J Neurosci 21: 2347–2360. 39. Ravizza T, Rizzi M, Perego C, Richichi C, Vel´ıskova´ J, et al. (2005) Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia 46: 113–117. 40. Dube´ C, Vezzani A, Behrens M, Bartfai T, Baram TZEtal (2005) Interleukin- 1beta contributes to the generation of experimental febrile seizures. Ann Neurol 57: 152–155. 41. Rao RS, Medhi B, Saikia UN, Arora SK, Toor JS, et al. (2008) Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat. Eur Neuropsychopharmacol 18: 760–767. 42. Galic MA, Riazi K, Henderson AK, Tsutsui S, Pittman QJ (2009) Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 36: 343–351. 43. Ravizza T, Noe´ F, Zardoni D, Vaghi V, Sifringer M, et al. (2008) Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. Neurobiol Dis 31: 327–333. 44. Marchi N, Fan Q, Ghosh C, Fazio V, Bertolini F, et al. (2009) Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis 33: 171–181. 45. Naitoh Y, Fukata J, Tominaga T, Nakai Y, Tamai S, et al. (1998) Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely- moving rats. Biochem Biophys Res Commun 155: 1459–1463. 46. Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, et al. (2005) Inhibition of astroglial nuclear factor kappa B reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med 202: 145–156. 47. Piermartiri TC, Vandresen-Filho S, de Arau´jo Herculano B, Martins WC, Dal’agnolo D, et al. (2009) Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. Neurotox Res 16: 106–115. 48. Kuijk LM, Beekman JM, Koster J, et al. (2008) HMG-CoA reductase inhibition induces IL-1b release through Rac1/PI3K/PKB-dependent caspase-1 activa- tion. Blood 112: 3563–3573. 49. Bovolenta R, Zucchini S, Paradiso B, Rodi D, Merigo F, et al. (2010) Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis- associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation 7: 81. 50. Eid T, Lee TS, Thomas MJ, Amiry-Moghaddam M, Bjørnsen LP, et al. (2005) Loss of perivascular aquaporin 4 may underlie deficient water and K+homeo- stasis in the human epileptogenic hippocampus. Proc Natl Acad Sci U S A 102: 1193–1198. 51. Seifert G, Schilling K, Steinhauser C (2006) Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci 7: 194–206. 52. Tian GF, Azmi H, Takano T, Xu Q, Peng W, et al. (2005) An astrocytic basis of epilepsy. Nat Med 11: 973–981. 53. Gibson RM, Rothwell NJ, Le Feuvre RA (2004) CNS injury: The role of the cytokine IL-1. Vet J 168: 230–237. PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24966